Technology | Population Health | January 28, 2016

Boston Scientific and Accenture Develop Digital Health Solution for Chronic Cardiovascular Conditions

Care Pathway Transformation solution designed to help providers make better-informed decisions based on patient population insights

January 28, 2016 — Boston Scientific Corp. and Accenture have developed a cloud-based, data-driven digital health solution for hospitals to help improve patient outcomes and reduce costs to treat patients with chronic cardiovascular diseases.

The solution, known as Advantics Care Pathway Transformation, is designed to enable providers to make more proactive and informed decisions based on insights into the patient population. The goal ultimately is improving the care a patient experiences from hospital stay through post-discharge care and in-home support.

The Care Pathway Transformation solution uses the Accenture analytics insights platform, which provides actionable insights into care coordination and patient population health patterns, revealing opportunities to improve their consistency and efficiency. The solution will focus on three key measurements:

  • Pathway Analytics: how a patient moves through the hospital system, how long each step takes and whether a patient can be better served by a more efficient system;
  • Care Management: how patients are diagnosed, treated and monitored, by whom and how often, as well as their ongoing vital signs and risk analysis; and
  • Patient Engagement: how patients are educated, monitored and receive communication during their hospitalization and after discharge.

The solution has been tailored for insight into patients with heart failure, but the companies plan to expand it to additional disease states.

In developing this solution, both companies worked with two of the largest hospitals in Scandinavia — Karolinska University Hospital in Sweden and Tampere Heart Hospital in Finland — to assess the current state of care delivery for heart failure patients and identify opportunities for improvement at each hospital. Heart failure has been identified as one of the costliest disease states to manage — resulting in about 2 percent of healthcare spending and accounting for an average 11-day hospital stay in Europe.

"The collaboration with Boston Scientific and Accenture exposed significant opportunities to increase provider collaboration and improve the quality of care that patients experience when coming to our hospital," said Kari Niemelä, M.D., chief executive officer, Tampere Heart Hospital. "For example, we identified a 25 percent unnecessary heart failure readmissions rate, and therefore a definite need for better care coordination, supported by modern technology and processes that can decrease overall costs."

The two companies initially plan to make the Care Pathway Transformation solution available to hospitals in the United Kingdom and Scandinavia, and expect to pilot projects throughout Europe and the United States soon.

For more information: www.bostonscientific.com, www.accenture.com

Related Content

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension| September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
MDISS Launches 'WHISTL' Network of Medical Device Security Testing Labs
News | Cybersecurity| August 23, 2017
The Medical Device Innovation, Safety and Security Consortium (MDISS) recently launched the first of more than a dozen...
HHS Unveils Improved Web Tool to Highlight Recent Health Information Breaches
News | Cybersecurity| August 21, 2017
The U.S. Department of Health and Human Services (HHS), Office for Civil Rights (OCR) recently launched a revised web...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Overlay Init